Aller au contenu principal
xMedica

NCT06605404ClinicalTrials.gov

Pan-tumor MRD Study

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

En recrutementAccepte des participants actuellement, selon la fiche du registre.
Contacter cette étude

En bref

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to…

Observationnelle1 350 participants recherchés47 sites1 pays

Catégories

Enregistré dans 1 registre

Une même étude peut être enregistrée dans plusieurs registres. Nous l'affichons une seule fois et renvoyons vers chaque fiche que nous détenons.

Les informations de l'essai sont affichées telles que publiées par le registre, dans leur langue d'origine.

Cette étude vous intéresse ?

Se connecter ou créez un compte pour manifester votre intérêt et suivre cette étude.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2024-09-20; recorded start 2025-01-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Not stated: No other studies from this sponsor are in this databaseCounted from the lead sponsor named in the record (Paradigm Health)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 7 conditions.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleLARGE

A large study: 1,350 participants (target), run at 47 sites.

How this score is built
  • Enrolment31/40

    1,350 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration10/10

    Planned over about 88 months

  • Sponsor scale0/10

    Paradigm Health has led 1 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Résumé

The purpose of this observational study is to collect clinical information, blood, and tumor tissue samples from participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors. The information collected will be used to develop tests to better understand cancer, for example, to improve cancer detection and to assess the risk of cancer coming back. Participants will receive routine standard of care from their doctor and their involvement is expected to last for approximately five and a half (5.5) years.

Affections

  • Muscle Invasive Bladder Urothelial Carcinoma
  • Esophageal Cancer
  • Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
  • Melanoma (Skin Cancer)
  • NSCLC (Non-small Cell Lung Cancer)
  • Pancreatic (Exocrine Only)
  • Mix of Solid Tumors (MOST)

Éligibilité

Éligibilité
SexeTous
Âges18 Years – Aucun maximum
Volontaires sainsNon
Méthode d'échantillonnageNON_PROBABILITY_SAMPLE

Population de l'étude

Study participants diagnosed with stage I, stage II, or operable stage III cancer in select solid tumors

Éligibilité telle qu'elle figure dans le registre

Eligibility Criteria: 1. Age 18 years or older. 2. Confirmed histological or cytological diagnosis of a malignant solid tumor that is either specified in one of the pre-defined tumor cohorts or meets the enrollment criteria for the Mix of Solid Tumors (MOST) cohort (Table 1). 3. Eligible for curative intent therapy, with surgical resection of cancer planned. a. If surgical resection has occurred, enrollment should occur within 3 months of surgical resection and before initiation of adjuvant therapy. 4. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2. 5. No systemic therapy for current cancer diagnosis administered before enrollment. 6. Willing and able to comply with required study procedures, including blood sample collection and primary tumor tissue submission from diagnostic biopsy or surgical excision. 7. Has completed all therapy (including endocrine therapy) 3 or more years ago for any previous invasive solid organ malignancy (with exception of nonmelanoma skin cancers) or hematologic malignancy. Individuals with a prior history of noninvasive (in situ) carcinomas may participate if they have received definitive treatment (no washout period required). 8. No concurrent diagnosis of another invasive cancer, except for nonmelanoma skin cancers. 9. No prior allogeneic hematopoietic stem cell transplant. 10. Able and willing to provide informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for the release of personal health information. Cohort Specific Criteria 11. Muscle-invasive urothelial carcinoma of the bladder and Melanoma Cohorts: Stage II or operable III cancer: 12. Esophageal, Gastric/GEJ, and NSCLC Cohorts: Stage I, II, or operable III cancer. 13. Pancreatic Cohort: Stage I, II or operable III cancer, exocrine only disease. 14. MOST cohort: Stage II or operable stage III solid tumor diagnosis that meets eligibility criteria and is not included in the other cohorts. The following tumor types are excluded: 1. Central nervous system (CNS) malignancies 2. Colorectal cancer 3. Breast cancer 4. Squamous cell skin cancer 5. Basal cell carcinoma 6. Gastrointestinal stromal tumors (GIST) 7. Thyroid cancer 8. Uveal melanoma 9. Low or intermediate grade neuroendocrine tumors ■ Eligible tumor types: High-grade neuroendocrine tumors, including neuroendocrine carcinomas, Merkel cell carcinomas, and small cell lung cancer are permissible 10. Hematologic cancers including multiple myeloma or other plasma cell dyscrasias, Hodgkin\'s lymphoma, non-Hodgkin\'s lymphoma, acute or chronic leukemias including chronic lymphocytic leukemia / small lymphocytic leukemia

Éligibilité en énoncés simples

Les critères de cette fiche n'ont pas encore été décomposés en énoncés distincts. Le texte du registre ci-dessus est complet et fait foi.

Conception de l'étude

Conception de l'étude
Type d'étudeObservationnelle
PhaseNon précisé dans la fiche du registre
RépartitionNon précisé dans la fiche du registre
Modèle d'interventionNon précisé dans la fiche du registre
Objectif principalNon précisé dans la fiche du registre
InsuNon précisé dans la fiche du registre
Recrutement1 350 participants recherchés

Promoteur et collaborateurs

  • Paradigm Health Promoteur

Groupes et interventions

  • Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

    Muscle Invasive Urothelial Carcinoma of the Bladder (MIBC)

  • Esophageal

    Esophageal cancer

  • Gastric and Gastroesophageal Junction (GEJ)

    Gastric and Gastroesophageal Junction (GEJ)

  • Melanoma

    Melanoma

  • Non-small cell lung (NSCLC)

    Non-small cell lung (NSCLC)

  • Pancreatic (exocrine only)

    Pancreatic (exocrine only)

  • Mix of Solid Tumors (MOST)

    Mix of Solid Tumors (MOST)

Interventions

  • Test diagnostique blood and tissue samples

    routine standard of care

  • Autre blood and tissue samples

    Routine standard of care

Critères de jugement

  1. Critère de jugement principal

    Blood and tissue biospecimen registry

    To establish a blood and tissue biospecimen resource in participants with operable solid tumors, with clinical, lab, radiographic, and pathology annotation for the discovery, development, and validation of MRD assays.

    Délai Observation from enrollment to 5.5 years after enrollment

Dates

Dates
Date de début8 janvier 2025 (réelle)
Achèvement principal1 décembre 2031 (estimée)
Achèvement1 avril 2032 (estimée)
Première publication20 septembre 2024 (réelle)
Dernière mise à jour24 septembre 2026
Résultats publiésNon précisé dans la fiche du registre
Statut vérifié pour la dernière foisseptembre 2026

Réelle signifie que l'événement a eu lieu. Estimée signifie que le promoteur s'y attend. Les deux ont un sens différent.

Lieux

47 sites sont en recrutement

United States

United States
ÉtablissementVilleÉtat ou régionStatut
Piedmont Cancer InstituteAtlantaGeorgiaEn recrutement
Guthrie Lourdes Memorial Hospital (GLMH)BinghamtonNew YorkEn recrutement
Alabama OncologyBirminghamAlabamaEn recrutement
Mohtaseb Cancer Center and Blood DisordersBullhead CityArizonaEn recrutement
Gabrail Cancer CenterCantonOhioEn recrutement
Cancer & Blood Specialists of ArizonaCasa GrandeArizonaEn recrutement
Carolina Oncology SpecialistsCharlotteNorth CarolinaEn recrutement
Oncology & Hematology Associates of West BrowardCoral SpringsFloridaEn recrutement
Baptist Health CorbinCorbinKentuckyEn recrutement
Pontchartrain Cancer CenterCovingtonLouisianaEn recrutement
Baptist Health HardinElizabethtownKentuckyEn recrutement
The Melanoma and Skin Cancer InstituteEnglewoodColoradoEn recrutement
San Juan Oncology AssociatesFarmingtonNew MexicoEn recrutement
Los Angeles Cancer Network (LACN)GlendaleCaliforniaEn recrutement
Southeastern Medical Oncology Center (SMOC)GoldsboroNorth CarolinaEn recrutement
The Cancer & Hematology Centers (CHC)Grand RapidsMichiganEn recrutement
Onocology Consultants P.A. (Oncology Consultants [OC Houston])HoustonTexasEn recrutement
Community Clinical TrialsKingwoodTexasEn recrutement
Lancaster General Hospital (UPenn)LancasterPennsylvaniaEn recrutement
Baptist Health LexingtonLexingtonKentuckyEn recrutement
Cancer Partners of NebraskaLincolnNebraskaEn recrutement
CARTILittle RockArkansasEn recrutement
Baptist Health LouisvilleLouisvilleKentuckyEn recrutement
Taylor Cancer Research CenterMaumeeOhioEn recrutement
Cancer Care Specialists of Illinois (CCSI)O'FallonIllinoisEn recrutement
Mid Florida Cancer CentersOrange CityFloridaEn recrutement
Ventura County Hematology Oncology SpecialistsOxnardCaliforniaEn recrutement
Oregon Health & Science University (OHSU)PortlandOregonEn recrutement
Virginia Cancer InstituteRichmondVirginiaEn recrutement
Mayo ClinicRochesterMinnesotaEn recrutement
Medical Oncology Associates of San Diego (MOASD)San DiegoCaliforniaEn recrutement
Medical Oncology Associates of San DiegoSan DiegoCaliforniaEn recrutement
Guthrie FoundationSayrePennsylvaniaEn recrutement
New York Cancer & Blood SpecialistsShirleyNew YorkEn recrutement
Christus Health HighlandsShreveportLouisianaEn recrutement
Highlands Oncology Group (HOG)SpringdaleArkansasEn recrutement
Cox HealthSpringfieldMissouriEn recrutement
Comprehensive Hematology Oncology (CHO)St. PetersburgFloridaEn recrutement
Stockton Hematology Oncology Med GroupStocktonCaliforniaEn recrutement
Northwest Medical Specialties (NWMS)TacomaWashingtonEn recrutement
Christus St. Michael'sTexarkanaTexasEn recrutement
Cotton O'Neil Cancer Center [Stormont Vail]TopekaKansasEn recrutement
Oklahoma Cancer Specialists and Research Institute (OCSRI)TulsaOklahomaEn recrutement
Carle HealthUrbanaIllinoisEn recrutement
Cancer Center of KansasWichitaKansasEn recrutement
Regional Medical Oncology CenterWilsonNorth CarolinaEn recrutement
Cancer Care Associates of York (CCAY)YorkPennsylvaniaEn recrutement

Documents de l'étude

Aucun document n'est lié dans cette fiche du registre.

Évolution au fil du temps

  1. 24 septembre 2026

    Site ajouté

    45 sites added (47 total)

    247